drugset
drugset / Trial / NCT05516121

VLT-015 in Patients With Schizophrenia

NCT05516121 ↗

Phase 1 Completed 15 enrolled CF Pharma, LLC
NaSingle-groupOpen-labelOther

Summary

15 stable patients diagnosed with schizophrenia take 100 mg of VLT-015 once a day, 200 mg of VLT-015 once a day and 200 mg of VLT-015 on two consecutive days with an interval of 24 hours between doses. PK parameters are measured, tolerability and safety of the product are evaluated.

Timeline

Start
2021-02-01
Primary completion
2022-09-30
Completion
2022-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject VLT-015 Unknown 100 mg —
Subject VLT-015 Unknown 200 mg —

Indications

schizophrenia